Table 2 Comparison of the frequency of mortality associated with all-cause pneumonia between adults aged ≥19 years with autoimmune inflammatory rheumatic diseases, human immunodeficiency virus infection, and malignant neoplasms. Mortality data from the general population of the State of Rio de Janeiro, Brazil, 2006–2018

From: Correction to: Mortality burden associated with all-cause pneumonia among adults with autoimmune inflammatory rheumatic diseases, human immunodeficiency virus infection, and malignancies: a population-based comparative study for informed decision-making in public health policies

  PMN-associated deaths, n
(AIRD group / comparator group)
non-PMN-associated deaths, n
(AIRD group / comparator group)
Odds ratio (95% CI) a P value
Disease groups, women
 CTD vs HIV 496 / 2227 1,250 / 5631 1.0 (0.89–1.12) 0.95
 CTD vs malignant neoplasms 496 / 11,313 1,250 / 117,308 4.1 (3.70–4.57) <0.0001
 RA vs HIV 215 / 2227 261 / 5631 2.1 (1.72–2.51) <0.0001
 RA vs malignant neoplasms 215 / 11,313 261 / 117,308 8.5 (7.12–10.24) <0.0001
Disease groups, men
 CTD vs HIV 102 / 3753 259 / 9858 1.0 (0.82–1.30) 0.77
 CTD vs malignant neoplasms 102 / 13,812 259 / 114,236 3.3 (2.58–4.09) <0.0001
 RA vs HIV 58 / 3753 56 / 9858 2.7 (1.88–3.93) <0.0001
 RA vs malignant neoplasms 58 / 13,812 56 / 114,236 8.6 (5.93–12.37) <0.0001
  1. a For between-group comparisons, the odds ratio formula is given by: (PMN-associated deaths in the CTD or RA group × non-PMN-associated deaths in the HIV or malignant neoplasm group) ÷ (non-PMN-associated deaths in the CTD or RA group × PMN-associated deaths in the HIV or malignant neoplasm group). This methodology has been previously applied in the assessment of mortality associated with the systemic connective tissue diseases [13]
  2. AIRD autoimmune inflammatory rheumatic disease, CI confidence interval, CTD systemic connective tissue diseases, HIV human immunodeficiency virus, PMN all-cause pneumonia, RA rheumatoid arthritis